New EU-funded research project for early prevention of diabetic kidney disease
People with diabetes have an increased risk of developing kidney disease which can ultimately lead to the need for dialysis or a kidney transplant. The expenditure on people with diabetes accounts for 15% of the European health care budget. A significant part of these costs are associated with diabetic kidney disease which accounts for up to 45% of end stage renal disease.
The new EU-funded multi-centre study PRIORITY, starting 1st of January 2012, will run over the next six years involving a wide range of European partners including universities, clinics and industry. "We will investigate early urinary markers of kidney disease to identify people who are at risk and to explore whether a specific, early treatment intervention can delay or prevent the onset of diabetic kidney disease", says Peter Rossing, lead investigator and coordinator of PRIORITY. Peter Rossing is Head of Steno Research Center, at Steno Diabetes Center in Denmark.
Translating new technology into personalised care
The urinary proteome analysis is an innovative technology developed by one of the partners in the project, Mosaiques Diagnostics in Germany. The approach has demonstrated its accuracy and reliability in more than 40 clinical trials so far and will be used to identify patients at risk as early as possible. Furthermore, the project aims at showing positive effects of treatment with aldosterone blockade on top of standard care among the at-risk patients. It is anticipated that about 20% are at-risk patients who will be assigned to aldosterone blocker or matching placebo.
Patients who are classified as being at low risk for progression to diabetic kidney disease will continue to receive standard care. "Our objective is to show that the early diagnosis with proteomic technology in combination with a specific therapy will be highly beneficial for the diabetic patients", says Professor Harald Mischak from Mosaiques Diagnostics.
The project will be carried out as a clinical trial including 3500 patients in a multi-centre study which involves 15 European partners. The project is funded by the EU’s Seventh Framework Programme (FP7).